Expert Says RSV Shots Will Have Significant Clinical Impact, Urges Public Funding and NIP Inclusion

Junichiro Nishi, Chair Vaccine Committee, Japanese Association for Infectious Diseases The first respiratory syncytial virus (RSV) vaccine is now available in Japan. GlaxoSmithKline launched Arexvy earlier this year for older adults, while Pfizer’s Abrysvo - approved for maternal immunization and...read more